Anteris Technologies Global Corp. (AVR)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$5.87-2.17%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Anteris Technologies Global Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.95M
EPS	—	-0.314
Annual ending 2026-12-31
Revenue	—	6.14M
EPS	—	-1.206
Annual ending 2027-12-31
Revenue	—	10M
EPS	—

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain financial stability after debt issuance	A supporting condition in Anteris Technologies Global Corp.'s published investment case. The stated target is No liquidity crisis or debt default post-May 2026 issuance.	Intact	Debt covenant breach or liquidity shortfall after debt issuance	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain financial stability after debt issuanceQualitative condition
Lease and utilize new office and warehouse spaceQualitative condition
Successful termination of development contributions with v2vmedtechQualitative condition
Revenue grows to at least $19.9 million in FY27Published status: Broken

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-44.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Anteris Technologies Global Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AVR is a speculative, development-stage healthcare story rather than an established earnings compounder. The long-term thesis is on watch: management is advancing the PARADIGM Trial, but the company is loss-making and recent financial performance has been weak.

What's priced into Anteris Technologies Global Corp.

AVR is valued at a substantial premium to peers, with optionality driving the valuation and low confidence in the valuation model. The evidence says that expensive valuation is priced in, but not the full combination of weak performance and turbulent conditions.

What the fundamentals likely do

Near term, earnings risk is elevated after repeated misses, including the August 2026 miss, and recent performance has lagged its industry cohort. Management says advancing the PARADIGM Trial is a priority, and reported revenue rose from $494,000 in Q1 to $1,009,000 in Q2 while operating cash outflows fell from $28.7 million to $20.8 million. These changes align with trial-related activity, but do not yet establish a stronger earnings base.

What Anteris Technologies Global Corp. hinges on

Over the multi-year view, the central swing factor is progress in the PARADIGM Trial and whether management continues to meet its stated execution milestones. Near term, a weakening jobs trend could add pressure to cyclical healthcare names, while continued strong results from sector bellwethers ABT, MDT, and SYK could sustain sector momentum; weaker results or guidance from those companies could remove that support.

Bottom line

AVR’s long-term thesis has a clinical-development basis, but current evidence shows losses, weak performance, elevated near-term risk, and a premium valuation. The 1-3 year view depends on trial execution and whether the business shows more durable financial progress. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

What could strengthen or challenge Anteris Technologies Global Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.95M
EPS	—	-0.314
Annual ending 2026-12-31
Revenue	—	6.14M
EPS	—	-1.206
Annual ending 2027-12-31
Revenue	—	10M
EPS	—

Measure / period

Management expectations

Analyst expectations

Quarter ending 2026-12-30

Revenue

—

2.95M

EPS

—

-0.314

Annual ending 2026-12-31

Revenue

—

6.14M

EPS

—

-1.206

Annual ending 2027-12-31

Revenue

—

10M

EPS

—

Key Factor

Why It Matters

Current Status

Break Condition

Latest Evidence

Maintain financial stability after debt issuance

A supporting condition in Anteris Technologies Global Corp.'s published investment case. The stated target is No liquidity crisis or debt default post-May 2026 issuance.

Intact

Debt covenant breach or liquidity shortfall after debt issuance

Qualitative condition

This condition has no defined numerical measure.

Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

FY2027 estimate observations · fmp

Snapshot

EPS

Revenue

EPS / revenue analysts

2026-07-24

Unavailable

1 / 3

2026-07-25

Unavailable

1 / 3

2026-07-26

Unavailable

1 / 3

2026-07-27

Unavailable

3 / 4

2026-07-28

Unavailable

3 / 4

2026-07-29

Unavailable

Date	Buy*	Hold
2026-05-01	4	0
2026-06-01	3	0
2026-07-01	3	0
2026-08-01	3	0
2026-09-01	3	0
2026-10-01	4	1

Anteris Technologies Global Corp. (AVR)

What could strengthen or challenge Anteris Technologies Global Corp.’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Historical risk context

Anteris Technologies Global Corp. outlook in detail

What kind of bet this is

What's priced into Anteris Technologies Global Corp.

What the fundamentals likely do

What Anteris Technologies Global Corp. hinges on

Bottom line

What could strengthen or challenge Anteris Technologies Global Corp.’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Historical risk context

Anteris Technologies Global Corp. outlook in detail

What kind of bet this is

What's priced into Anteris Technologies Global Corp.

What the fundamentals likely do

What Anteris Technologies Global Corp. hinges on

Bottom line

Analyst view

Price-target changes

Next proof point

Bottom line